We are live on ! Find out more
NAVB

Navidea Biopharmaceuticals Inc.
NAVB

Delisted

NAVB was delisted on the 5th of October, 2023.

Back to rankings

25 hedge funds and large institutions have $1.19M invested in Navidea Biopharmaceuticals Inc. in 2022 Q1 according to their latest regulatory filings, with 1 funds opening new positions, 2 increasing their positions, 10 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

19% less funds holding

Funds holding: 31 → 25 (-6)

29% less capital invested

Capital invested by funds: $1.68M → $1.19M (-$489K)

78% less call options, than puts

Call options by funds: $60K | Put options by funds: $270K

80% less repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 10

86% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 7

Holders
25
Holders Change
-6
Holders Change %
-19.35%
% of All Funds
0.39%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
2
Reduced
10
Closed
7
Calls
$60K
Puts
$270K
Net Calls
-$210K
Net Calls Change
+$73K

Top Buyers

Rank Fund Capital Flow
1
Group One Trading
Group One Trading
Illinois
+$57.5K
2
Morgan Stanley
Morgan Stanley
New York
+$186

Top Sellers

Rank Fund Capital Flow
1
Commonwealth Equity Services
Commonwealth Equity Services
Massachusetts
-$51K
2
Two Sigma Advisers
Two Sigma Advisers
New York
-$45.3K
3
Citadel Advisors
Citadel Advisors
Florida
-$37.6K
4
Two Sigma Investments
Two Sigma Investments
New York
-$33K
5
Simplex Trading
Simplex Trading
Illinois
-$13.2K
Name Holding Trade Value Shares
Change 		Change in
Stake
Vanguard Group
1
Vanguard Group
Pennsylvania
$582K – – –
Group One Trading
2
Group One Trading
Illinois
$174K +$57.5K +62,700 +40%
BlackRock
3
BlackRock
New York
$135K -$2.52K -2,754 -2%
BCM
4
Bridgeway Capital Management
Texas
$81K – – –
Geode Capital Management
5
Geode Capital Management
Massachusetts
$76K – – –
ACM
6
Allred Capital Management
Texas
$40K -$1.48K -1,616 -3%
Northern Trust
7
Northern Trust
Illinois
$31K – – –
State Street
8
State Street
Massachusetts
$19K – – –
Citadel Advisors
9
Citadel Advisors
Florida
$14K -$37.6K -41,000 -70%
VF
10
Virtu Financial
New York
$11K -$9.83K -10,726 -43%
Two Sigma Advisers
11
Two Sigma Advisers
New York
$9K -$45.3K -49,400 -80%
PFO
12
Pathstone Family Office
New Jersey
$8K – – –
Wells Fargo
13
Wells Fargo
California
$4K -$17 -19 -0.4%
Simplex Trading
14
Simplex Trading
Illinois
$3K -$13.2K -14,419 -77%
TRCT
15
Tower Research Capital (TRC)
New York
$3K -$1.44K -1,566 -28%
Bank of America
16
Bank of America
North Carolina
$1K -$177 -193 -10%
JP Morgan Chase
17
JP Morgan Chase
New York
$1K – – –
KFS
18
Kelly Financial Services
Massachusetts
$40 – – –
Commonwealth Equity Services
19
Commonwealth Equity Services
Massachusetts
– -$51K -51,203 Closed
Two Sigma Investments
20
Two Sigma Investments
New York
– -$33K -33,467 Closed
Wolverine Trading
21
Wolverine Trading
Illinois
– -$11.4K -12,484 Closed
UBS Group
22
UBS Group
Switzerland
– -$8.49K -9,266 -99%
Osaic Holdings
23
Osaic Holdings
Arizona
– -$2K -2,150 Closed
IA
24
IFP Advisors
Florida
– -$1K -50 Closed
CA
25
CoreCap Advisors
Michigan
– -$1K -45 Closed
1
2

NAVB Hedge Fund Activity: Q1 2022 in Review

25 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Navidea Biopharmaceuticals Inc. (NAVB) for Q1 2022, worth a combined $1.19M — down 29% from $1.68M a quarter earlier.

Sellers outnumbered buyers: 7 funds closed out of NAVB and 1 opened new positions — a net loss of 6 holders — while 10 trimmed existing stakes and 2 added.

The largest buyer was Group One Trading, adding an estimated $57.5K. The largest seller was Commonwealth Equity Services, exiting entirely with an estimated $51K sold.

  • 25 institutional investors held Navidea Biopharmaceuticals Inc. (NAVB) as of Q1 2022, down from 31 in Q4 2021.
  • Funds reported $1.19M of Navidea Biopharmaceuticals Inc. stock for Q1 2022, down 29% quarter-over-quarter.
  • 1 fund opened new Navidea Biopharmaceuticals Inc. positions in Q1 2022 and 7 closed out, a net change of -6 holders.
  • The largest Navidea Biopharmaceuticals Inc. buyer in Q1 2022 was Group One Trading, an estimated $57.5K added.
  • The largest Navidea Biopharmaceuticals Inc. seller in Q1 2022 was Commonwealth Equity Services, an estimated $51K sold.

Based on aggregated 13F filings for Q1 2022.